JULIET试验五年分析:替沙仑赛治疗复发/难治性大B细胞淋巴瘤
JULIET是一项单臂、开放标签、多中心、全球II期试验,纳入115例接受替沙仑赛输注的复发/难治性大B细胞淋巴瘤患者,中位随访74.3个月。中位缓解持续时间未达到,缓解者60个月无复发生存概率为61%,60个月无进展生存概率为28%,总生存概率为32%。未报告新的安全性信号或继发性T细胞恶性肿瘤。
要点
- 缓解者60个月无复发生存概率为61%,中位缓解持续时间未达到。
- 全部输注患者60个月总生存概率为32%,达到完全或部分缓解者为56%。
- 未报告新的安全性信号或继发性T细胞恶性肿瘤。
核心结论
- 这些发现持续支持替沙仑赛在部分复发/难治性大B细胞淋巴瘤患者中具有治愈潜力。
研究设计与样本
- 单臂、开放标签、多中心、全球II期JULIET试验(ClinicalTrials.gov标识NCT02445248),纳入115例接受替沙仑赛输注的复发/难治性大B细胞淋巴瘤患者,中位随访74.3个月。
主要发现
- 中位缓解持续时间未达到;缓解者60个月无复发生存概率为61%。
- 女性、基线国际预后指数风险因素少于两个或基线I/II期疾病者观察到更高的无复发生存概率(缓解持续时间>70%)。
- 60个月无进展生存概率估计为28%。
- 全部输注患者60个月总生存概率为32%,达到完全或部分缓解者为56%。
- 输注后任何时间达到缓解相关的基线特征包括:复发 versus 难治性疾病、一种 versus 两种或以上桥接方案、乳酸脱氢酶≤正常上限(ULN) versus >ULN、C反应蛋白<15 mg/L versus >15 mg/L。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JULIET trial (ClinicalTrials.gov identifier: NCT02445248), with a median follow-up of 74.3 months. The median duration of response (DOR) was not reached; the 60-month, relapse-free probability was 61% among responders. Higher relapse-free probability (DOR >70%) was observed in females and those with less than two baseline International Prognostic Index risk factors or with baseline stage I/II disease. The estimated probability of progression-free survival at 60 months was 28%. The probability of overall survival (OS) at 60 months was 32% for all infused patients and 56% for those achieving complete or partial response. Baseline characteristics associated with achieving a response at any time after infusion included relapsed versus refractory disease, one versus two or more bridging regimens, lactate dehydrogenase level ≤upper limit of normal (ULN) versus >ULN, and C-reactive protein levels <15 mg/L versus >15 mg/L. Baseline characteristics associated with long-term OS included lactate dehydrogenase ≤ULN and C-reactive protein <15 mg/L. No new safety signals or secondary T-cell malignancies were reported. These findings continue to support the curative potential of tisagenlecleucel in a subset of patients with r/r LBCL.
引用
- Maziarz RT, Bishop MR, Tam CS, et al. Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 41252666. doi:10.1200/JCO-25-00507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。